Bispecific antibodies (BsAb) are immunoglobulin (Ig)-based molecules that can simultaneously bind to two different epitopes on either the same or distinct antigens. Both laboratory and early clinical studies to date have demonstrated that BsAb may have significant potential application in cancer therapy (1-3). The primary use of BsAb has been to redirect cytotoxic immune effector cells for enhanced killing of tumor cells. In this context, one arm of the BsAb binds an antigen on the tumor cell, and the other binds a determinant expressed on effector cells, such as CD3, CD16, or CD64, which are expressed on T lymphocytes, natural killer cells, or other mononuclear cells (4-6, for review, see 7) . By cross-linking tumor and effector cells, the BsAb not only brings the effector cells within the proximity of the tumor cells but also simultaneously triggers their activation, leading to effective tumor cell-killing. In addition, BsAb has also been used to enrich the tumor/normal tissue localization ratio of chemo-or radio-therapeutic agents. In this setting, one arm of the BsAb binds an antigen expressed on the cell targeted for destruction, and the other arm binds a chemotherapeutic drug, radioisotope, or toxin. The naked BsAb is administered first, and after sufficient time has passed for the BsAb to bind tumor cells and to clear from normal tissue, the cytotoxic molecule is delivered, with rapid accumulation in the tumor, because of its affinity for the tumor bound BsAb (8) (9) (10) (11) . Recently, a novel concept has emerged -the development of BsAb that target simultaneously two tumor-associated antigens (e.g., growth factor receptors) for down-regulation of multiple cell proliferation/survival pathways, which provides enhanced antitumor activity (12) (13) (14) (15) .
A major obstacle in the general development of BsAb has been the difficulty of producing materials of sufficient quality and quantity for both preclinical and clinical studies. Initially, the main route to the production of BsAb was by co-expression of both the light chains (LC) and both the heavy chains (HC) of two parent antibodies of different specificities (antibody A and antibody B) in a single cell through either the hybrid hybridoma technique (16) or DNA co-transfection. Unfortunately, assuming that all the four polypeptide chains are equally expressed and there is no pairing preference between any particular LC and HC, in addition to the desired heterodimeric BsAb product (LC A -HC A plus LC B -HC B ), there are also a large number of undesired products formed from the ten molecules that result from the 16 permutations LC and HC pairings. Consequently, the desired bindingcompetent BsAb are a minor product (in theory, an eighth of the total), and purification from the other products is very difficult. Another traditional method for BsAb production is chemical conjugation of two antibodies (or their fragments) of different specificities (17) . The chemical modification process may inactivate the antibody or promote aggregation. As purification from undesired products remains difficult, the resulting low yield and poor quality BsAb makes this process, like the hybrid hybridoma and DNA cotransfection, unsuitable for the large scale production required for clinical development.
In recent years, a variety of recombinant methods have been developed for the efficient production of BsAb, especially for BsAb antibody fragments (1, 18, 19) . On the other hand, the successful design and production of full length IgG-like, i.e., Fc domain-containing, BsAb has been generally limited (20, 21) . In this report, we describe a novel recombinant method for the production of an Fc domain-containing BsAb molecule by direct fusion of a single variable domain (sVD) antibody to the N-terminus of the LC of a functional IgG antibody of a different specificity. The resulting BsAb molecule was expressed in mammalian cells and purified by Protein A chromatography. Further, the BsAb retained the binding specificities and the receptor-neutralizing activities of both of the parent antibodies.
EXPERIMENTAL PROCEDURES
Proteins and cells --Recombinant mouse platelet derived growth factor receptor α (mPDGFRα)-Fc and mouse vascular endothelial growth factor receptor 2 (mVEGFR2)-Fc fusion proteins, and human PDGF-AA were purchased from R&D Systems (Minneapolis, MN). VEGF protein was expressed in baculovirus and purified at ImClone Systems (New York, NY) following the procedure described elsewhere (22) . eEnd.1 cells, a murine endothelium line transformed by polyoma middle T oncogene, was a kind gift from Dr. M. Pepper of University Medical Center, Geneva, Switzerland. A control antibody, 1C11, an antibody directed against human VEGFR2, was produced at ImClone Systems (23, 24) .
Selection of anti-mPDGFRα antibodies from a phage display Fab library --
A large naïve human Fab phage display library from Dyax (containing 3.7x10 10 clones) (25, 26) was used to select antibodies directed against mPDGFRα-Fc protein. Briefly, the library stock (100 µl) was grown to log phase in 20 ml of 2YTAG medium (2YT containing 100 µg/ml of ampicillin and 2% of glucose), rescued with M13K07 helper phage, and amplified overnight in 2YTAK medium (2YT containing 100 µg/ml of ampicillin and 50 µg/ml of kanamycin) at 30˚C. The phage preparation was precipitated in 4% PEG, 0.5 M NaCl, and then resuspended in 1 ml of 3% fat-free milk/PBS containing 240 µg/ml of an unrelated human IgG and incubated at 37˚C for 1 h to block nonspecific binding and to deplete phages displaying Fab directed against human IgG Fc fragment. For each round of selection, mPDGFRα-Fccoated Maxisorp Star tubes (Nunc, Rosklide, Denmark) were first blocked with 3% milk/PBS at 37˚C for 1 h, and then incubated with the phage preparation at room temperature (RT) for 1 h. The tubes were washed 15 times with PBS containing 0.1% Tween 20 followed by 15 washes with PBS. The bound phage was eluted at RT for 10 min with 1ml of a freshly prepared solution of 100 mM triethylamine (Sigma, St Louis, MO). The eluted phages were incubated with 10 ml of mid-log phase TG1 cells at 37˚C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted, plated onto three 2YTAG plates, and incubated overnight at 30˚C. All of the colonies grown on the plates were scraped into 3 to 5 ml of 2YTA medium, mixed with glycerol (final concentration: 10%), aliquoted, and stored at -80˚C. For subsequent rounds of selection, the phage stock (100 µl) from the previous round of selection was amplified and used for selection followed the procedure described above on Maxisorp Star tubes coated with decreasing amount of mPDGFRα-Fc (50 µg/ml, 10 µg/ml and 2 µg/ml for the 1 st , the 2 nd and the 3 rd round of selections, respectively).
ELISA screening for antibodies with binding and blocking activities --Individual TG1 clones recovered after each round of selection were randomly picked and grown at 37˚C in 96-well plates. To produce phage, the cells were rescued with M13K07 helper phage as describe above. To produce soluble Fab, the cells were incubated in 2YTA medium containing 1mM of isopropyl-1-thio-β-D-galactopyranoside (IPTG, Sigma) at 30˚C overnight. For binding ELISA, 96-well microtiter plates (Nunc) were coated with mPDGFRα-Fc (50 µl at 1 µg/ml, 4˚C overnight). The amplified phage preparation or the cell culture supernatant containing soluble Fab was blocked with 1⁄6 volume of 18% milk/PBS at RT for 1 h and added to the mPDGFRα-Fccoated plates. After incubation at room temperature for 1 h, the plates were washed 3 times with PBST. For phage ELISA, the plates were incubated with a mouse anti-M13 phage antibody-HRP conjugate (Amersham Biosciences, Piscataway, NJ), and for Fab ELISA, the plates were incubated with a rabbit anti-human-Fab antibody-horse radish peroxidase (HRP) conjugate (Jackson ImmunoResearch Lab., West Grove, PA). The plates were then washed 3 times, TMB peroxidase substrate (KPL, Gaithersburg, MD) was added, and the absorbance at 450 nM was read using a microplate reader (Molecular Device, Sunnyvale, CA).
For blocking ELISA, phage or Fab supernatant were mixed with a fixed amount of mPDGFRα-Fc (0.5 µg/ml) and incubated at RT for 30 min. The mixture was then transferred to 96-well plates precoated with PDGF-AA (0.5 µg/ml) and incubated at RT for 1 h. The plates were then incubated at RT for 1 h with a rabbit anti-human-Fc antibody-HRP conjugate (Jackson ImmunoResearch Lab.), and developed as described above to quantify the amount of plate-bound mPDGFRα-Fc protein.
Identification of anti-mVEGFR2
antibody 2B4 --Anti-mVEGFR2 antibody, 2B4, was isolated from the Dyax Fab phage library following the same procedure described above on Maxisorp Star tubes coated with mVEGFR2-Fc fusion protein. 2B4 binds specifically to mVEGFR2 and blocks efficiently mVEGFR2/VEGF interaction (our unpublished results).
Expression and purification of soluble
Fab fragments --Phagemids of the individual selected clones were used to transform a nonsuppressor E.coli host HB2151. Expression of the Fab fragments in HB2151 and purification of the soluble Fab proteins from the periplasmic extracts of the E.coli were carried out as previously described (26) .
The Fab proteins were purified using Protein G columns following the manufacturer's protocol (Amersham Biosciences). The purity and the molecular size of the purified proteins were analyzed by electrophoresis using a NuPAGE TM 4-12% Bis-Tris gel (Invitrogen, Carlsbad, CA) followed by visualization by staining with SimplyBlue TM SafeStain (Invitrogen).
Construction of bispecific antimPDGFRα x anti-mVEGFR2 antibody based on the single VH domain antibody 1F2 --The BsAb was prepared using the single VH domain of the anti-mPDGFRα antibody, 1F2, and the variable domains (both VL and VH) from the conventional anti-mVEGFR2 antibody, 2B4, as the building blocks (Fig. 3) . In this construct, 1F2 VH domain was linked on its Cterminus via a 5 amino acid linker, Ala-SerThr-Lys-Gly, to the N-terminus of 2B4 LC. The resultant polypeptide, 1F2(VH)-2B4(VL)-CL, was then co-expressed with the 2B4 HC, 2B4(VH)-CH1-CH2-CH3, to form the bispecific molecule, 1F2-2B4IgG. The BsAb construct was transiently expressed in COS-7 cells and purified using Protein A affinity chromatography. The purity of the BsAb was assayed by SDS-PAGE analysis under both reducing and non-reducing conditions, and the protein concentrations were determined by ELISA, using an anti-human Fc antibody as the capturing agent and an anti-human κ chain antibody-HRP conjugate as the detection agent. A clinical grade antibody, IMC-C225, an antibody directed against human epidermal growth factor receptor, was used as the standard for calibration.
Quantitative receptor binding and blocking assays --Two different assays were carried out to examine the binding specificity and efficiency of the BsAb. In the first assay, the cross-linking assay, the BsAb was tested for their capability in simultaneously binding two target receptors: the BsAb or the monospecific antibodies (5 nM) were first incubated with mVEGFR2 or mPDGFR-α (100 ng) in solution and then transferred to a microtiter plate coated with the second receptor, mPDGFR-α or mVEGFR2 (100 ng/well), followed by incubation with a biotin-labeled polyclonal antibody to the first receptor (the receptor in solution), mVEGFR2 or mPDGFR-α. The plate was then developed as described above after further incubation with a streptoavidin-HRP conjugate. In the second assay, the direct binding assay, various amounts of purified antibodies were added to mPDGFRα-Fc or mVEGFR2-Fc-coated plates (1 µg/ml), and incubated at RT for 1 h, after which the plates were washed 3 times with PBST. The plates were then incubated at RT for additional 1 h with a rabbit anti-human Fab antibody-HRP conjugate (Jackson ImmunoResearch Lab.). The plates were washed and developed. In the blocking assay, various amounts of antibodies were first mixed with a fixed amount of mPDGFRα-Fc or mVEGFR2-Fc (0.5 µg/ml) and incubated at RT for 30 min. The mixture was then transferred to 96-well plates precoated with rhPDGF-AA or VEGF (0.5 µg/ml) and incubated at RT for 1 h. After washing 3 times, the plates were incubated with an antihuman Fc antibody-HRP conjugate, and developed as described above. IC50, the antibody concentration that yielded 50% blockade of mPDGFRα or mVEGFR2 from binding to its respective ligand, was determined.
Antibody affinity determination --The binding kinetics of various antibodies to their target receptors were measured using a BIAcore 3000 biosensor (BIACORE, Inc., Uppsala, Sweden). Briefly, mPDGFRα or mVEGFR2-Fc fusion protein was immobilized onto a sensor chip and soluble antibodies were injected at concentrations ranging from 1.5 nM to 100 nM. Sensorgrams were obtained at each concentration and were evaluated using the program, BIA Evaluation 2.0. The affinity constant, Kd, was calculated from the ratio of dissociation rate (koff)/association rate (kon).
Receptor phosphorylation assay --eEnd.1 cells were first examined for
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expression of mVEGFR2 and mPDGFRα via FACS analysis. Briefly, the cells were incubated with 2B4 IgG, 1F2-CH/CL or 1F2-2B4IgG (10 µg/ml) at 4ºC for 1 h, followed by incubation with a PE-labeled goat anti-human Fc antibody (Jackson ImmunoResearch Lab.) for an additional hour, and analysis on a Guava Easycyte System (Guava Technologies, Inc. Hayward, CA). In receptor phosphorylation assay, eEnd.1 cells were plated onto 6 cm dishes and grown to 70-80% confluence, after which the cells were washed twice in PBS and cultured overnight in serum free medium. The cells were first incubated with various antibodies at 37°C for 30 min, followed by stimulation with VEGF or PDGF-AA at 37°C for 15 min. The cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% TritonX-100, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 0.5 mM Na 3 VO 4, 1 µg/ml leupeptin, 1 µg/ml pepstatin, and 1 µg/ml aprotinin) for 1 h, followed by centrifugation of the lysate at 12, 000 rpm for 10 min at 4°C. The receptors were immunoprecipitated from the cell lysate supernatant by an anti-mPDGFRα (eBioscience, San Diego, CA) or an antimVEGFR2 antibody (Santa Cruz Biotech, Santa Cruz, CA), followed by the addition of 20 µl of ProA/G-sepharose beads (Santa Cruz Biotech). The precipitated receptor proteins were resolved on a 4-12% Nupage Bis-Tris gel (Invitrogen) and transferred to a polyvinylidene difluoride membrane. Phospho-mVEGFR2 and phosphomPDGFRα were detected on the blot using an anti-phospho-tyrosine antibody-HRP conjugate (Santa Cruz Biotech). Total receptor proteins loaded on the gel were assayed with antibodies to mPDGFRα or mVEGFR2 (both from Santa Cruz Biotech). and 1F9 lack most VL domain due to an inframe gene deletion -but possess an intact CL domain; whereas clone 1C10 has a frame-shift mutation within the complementarity determining region 3 (CDR3) of VL resulting in reading frame shift and a stop codon which leads to deletion of the entire CL, and clone 3G7 has a stop codon at the 5' end of VL gene due to a frame-shift mutation leading to the loss of the entire LC (Fig. 1) . Both clone 1C10 and 3G7 Fab-like fragments expressed very poorly in E.coli because of the lacking of the CL domain.
RESULTS

Identification of single VH domain antibodies to mPDGFRα from a Fab phage display library --
The Fab fragments of six clones were expressed in E. coli, purified by affinity chromatography using Protein-G column, and analyzed by SDS-PAGE (Fig. 2) . Under nonreducing conditions, Fabs with complete light and heavy chains, clone 1A11, 1E10, 3B2 and 3F3, yielded a single protein band with molecular weight of approximately 50 kDa ( Fig. 2A) . On the other hand, Fab fragments of 1F2 and 1F9 gave a small band of ~ 37.5 kDa due to the lack of VL domain (Fig. 2B) . Under reducing conditions, conventional Fab fragment showed two bands, the LC and the VH-CH1 fragment, of about the same size (~25 kDa), which was not distinguishable under the electrophoresis condition (Fig. 2B ). 1F2 and 1F9 Fabs yielded two bands that were resolved under the electrophoretic conditions, the upper bands correlates with the normal size VH-CH1 fragment, and the lower bands represents the CL fragment only (~12. 5 kDa) (Fig. 2B) .
mPDGFRα binding and mPDGFRα/PDGF-AA blocking by the antimPDGFRα antibodies --Purified Fab fragments from six clones were compared quantitatively in their binding efficiency to mPDGFRα and their potency in blocking mPDGFRα/PDGF-AA interaction. Clone 1F2 Fab, a single VH domain clone, is the most efficient binder to the receptor, followed by 1F9, another VH domain-only clone, and then the conventional Fab fragments, clone 1A11, 1E10, 3F3 and 3B2 (Fig. 3A) . Clone 1F2 is also the most potent blocker to receptor/ligand interaction, with an IC50 of 12 nM, which is followed by clone 1F9 (IC50, 57 nM), 1E10 (IC50, 140 nM), 1A11 (IC50, 220 nM) (Fig. 3B) . Clone 3B2, a weak blocker in phage-based ELISA, failed show any blocking activity as soluble Fab protein. The control clone, 3F3, binds well to the receptor, but does not block receptor/ligand interaction.
The binding kinetics of various antimPDGFRα clones were determined by surface plasmon resonance on a BIAcore instrument. Consistent with ELISA binding assay, 1F2 showed highest binding affinity with a Kd of 0.42 ± 0.21 nM (kon, 9.2 ± 4.2 x 10 5 1/Ms, koff, 3.1 ± 0.76 x 10 -4 1/s), which is followed by clone 1F9 (Kd, 2.1 ± 0.75 nM) and clone 1E10 (Kd, 12.2 ± 2.9 nM). When clone 1F2 was converted into a divalent Fab form (VH-CH1 / VH-CL), the affinity was further increased to 0.08 nM, representing a 5-fold enhancement over the monovalent 1F2 Fab. As a comparison, the divalent IgG form of clone 1E10 has a binding affinity of 0.81 ± 0.34 nM (data not shown).
Identification of the anti-mVEGFR2 antibody 2B4 --The
anti-mVEGFR2 antibody, 2B4, was isolated from the Dyax Fab phage library by selecting on Maxisorp Star tubes coated with mVDGFR2-Fc fusion protein (Fig. 1). Fab fragment of 2B4 binds specifically to mVEGFR2 and blocks mVEGFR2/VEGF interaction. The binding affinity of 2B4 Fab and IgG to mVEGFR2 was 6.7 ± 3.0 nM and 0.39 ± 0.1 nM, respectively, as determined by BIAcore analysis. 2B4 IgG blocks mVEGFR2/VEGF interaction with an IC50 value of approximately 3.5 nM.
Construction and expression of sVD antibody-based BsAb --
The BsAb construct was prepared using the variable domains from the single VH domain antibody 1F2 and the conventional antibody, 2B4 (Fig. 4A) . 1F2 VH was first fused to the N-terminus of 2B4 VL via a 5-amino acid linker to form 1F2VH-2B4 LC, which was then co-expressed with the intact HC of 2B4 (Fig. 4A) . As a control, a bivalent 1F2 molecule, 1F2-CH/CL, was also created by co-expression the 1F2VH-CH1-CH2-CH3 fusion along with the CL domain (Fig. 4A) . All the antibody molecules were transiently expressed in COS-7 cells and purified from the supernatant of cell cultures by affinity chromatography using Protein A columns.
The purified antibodies were analyzed by SDS-PAGE under both non-reducing and reducing conditions. When assayed under non-reducing conditions, the BsAb showed a single protein band of approximately 175 kDa, whereas the divalent 1F2-CH/CL demonstrated a single band at ~125 kDa, compared to that of 150 kDa of the monospecific 2B4 IgG (Fig. 4B) . The two polypeptides of the antibodies were resolved under reducing conditions. While 2B4 IgG yielded two bands of 50 kDa (the HC) and 25 kDa (the LC), 1F2-CH/CL gave two species of 50 kDa (the HC) and 12.5 kDa (the CL domain). As expected, 1F2-2B4IgG gave rise to two bands of 50 kDa (the HC) and 37.5 kDa (the 1F2VH-2B4 LC fusion).
Dual specificities of sVD antibodybased BsAb --A number of assays were used to confirm the BsAb molecules were capable of binding to both mPDGFRα and mVEGFR2. In the first assay, the crosslinking assay, we examined whether the BsAb could bind to both its targets simultaneously. The antibodies were first incubated with a receptor in solution and transferred to a 96-well plate coated with the second receptor. The plate was then incubated with a biotin-labeled antibody to the receptor in solution, followed by a streptoavidin-HRP. As shown in Fig. 5A and 5B, only the BsAb, but not the parent monospecific 2B4 IgG and 1F2-CH/CL, was able to cross-linking the two target receptors.
In the second assay, the BsAb were compared to their monospecific counterparts in antigen-binding efficiency. Various amounts of antibodies were added to 96-well plates coated with mPDGFRα or mVEGFR2 and assayed for their efficiency in binding to the receptors. While 1F2-CH/CL and 2B4 IgG bound only to their respective targets, the BsAb reacted to both immobilized mPDGFRα and mVEGFR2 ( Fig. 5C and  5D ). The ED50 values, i.e., the antibody concentrations that yield 50% of maximum binding, to mPDGFRα were 0.11 nM and 0.83 nM, for 1F2-CH/CL and 1F2-2B4IgG, respectively, and to mVEGFR2 were 0.19 nM and 4.8 nM, for 2B4 IgG and 1F2-2B4IgG, respectively. On BIAcore analysis, the BsAb binds to both mPDGFRα and VEGFR2 with an affinity that is higher than that of its monovalent, monospecific counterparts, 1F2 and 2B4 Fab (Table 2) . On the other hand, the binding affinity of the BsAb is ~ 6-fold lower in mPDGFRα binding, and 4-fold lower in mVEGFR2 binding, compared to its respective monospecific bivalent molecules, 1F2-CH/CL and 2B4 IgG (Table 2) . When examined on binding to cell surface-expressed receptors on eEnd.1 cells (the cells that express both mPDGFRα and mVEGFR2), the BsAb demonstrated, however, higher efficiency than either of the parent monospecific bivalent antibodies (Fig. 5E) . The mean fluorescence intensity (MFI) on the cells were 15.7, 31 and 36.9, for 1F2-CH/CL (for mPDGFRα binding), 2B4 IgG (for mVEGFR2 binding) and 1F2-2B4IgG (for both mPDGFRα and mVEGFR2 binding), respectively. Fig. 6 shows that the BsAb inhibit both mPDGFRα and mVEGFR2 from binding to their respective ligand, PDGF-AA and VEGF. The IC50 of the BsAb for blocking mPDGFRα/PDGF-AA is ~ 24 nM, compared to that of 2.7 nM for 1F2-CH/CL. On the other hand, the IC50 for blocking mVEGFR2/VEGF interaction are ~ 13.5 nM and 3.5 nM for 1F2-2B4IgG and 2B4 IgG, respectively (Fig. 6 ). As expected, 2B4 IgG had no effects on mPDGFRα/PDGF-AA interaction, nor did 1F2-CH/CL have any effects on mVEGFR2/VEGF interaction.
The BsAb inhibits ligand-induced activation of both mVEGFR2 and mPDGFRα --
The biological activity of the BsAb was investigated using eEnd.1 cells, a murine endothelial cell line that expresses both mPDGFRα and mVEGFR2 receptors. As shown in Fig. 7 , the BsAb inhibited both PDGF and VEGF-stimulated phosphorylation of mPDGFRα and mVEGFR2 receptors, whereas its monospecific parent antibodies only blocked the activation of a single receptor stimulated by its cognate ligand. As a control, the anti-EGFR antibody, C225, did not have any effect on ligand-stimulated activation of either receptor.
DISCUSSION
Here we describe an efficient approach for the production of an Fc domain-containing, IgGlike, BsAb by recombinant fusion of a sVD antibody to the N-terminus of an intact IgG antibody of different specificity. The BsAb is
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functionally expressed in mammalian cells and is capable of binding both of its target antigens. Further, the BsAb retained the activities of both parent antibodies in blocking receptor/ligand interaction and in neutralizing ligand-induced biological activities. We believe that this approach of BsAb production is applicable to antibodies recognizing any pair of antigens. By using the sVD antibody as the building blocks it is also possible to produce IgG-like antibody molecule that is tetravalent (but monospecific) to the same antigen.
Significant progresses have been made in the engineering and production of small BsAb fragments, e.g., diabody, minibody and FabscFv fusion protein (28-31, for reviews, see 18, 19, 32) . These BsAb fragments may possess some advantages over the full length IgG-like molecules for certain clinical applications, such as for tumor radioimaging and targeting, owing to its better tissue penetration and faster clearance from the circulation. On the other hand, IgG-like BsAb may prove to be better choices over smaller BsAb fragments for other in vivo applications, specifically for oncology indications, by providing the Fc domain that not only confers long serum half-life but also supports secondary immune function, such as antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. Unlike their fragment counterparts, engineering and production of recombinant IgG-like BsAb has been, however, rather technically challenging and the success in the field has been much limited. A number of approaches have been exploited in the past several years for efficient expression of Fc domain-containing BsAb molecules in mammalian cells (for reviews, see 20, 21) . For example, production of homogeneous full-length IgG-like BsAb has been achieved by the so-called "knobs-intoholes" engineering for efficient Ig CH3 domain heterodimerization plus the use of a common LC shared by two antibodies of different specificities (33) (34) (35) . While functional IgG-like BsAb were formed with high yield (> 95%), an obvious drawback of this method is that the inclusion of multiple mutations in the CH3 domains might pose an immunogenic risk in a therapeutic setting. Furthermore, it requires the identification of antibodies with common LC, which is rather infrequent, particularly for high affinity antibodies. Alternatively, IgG-like BsAb have also been produced by linking two single chain Fv (scFv) of different specificities onto both the N-terminal of the constant light (CL) and the first constant heavy (CH1) chains [the "(scFv)4-IgG"] (14, 36), or by fusing a scFv to the Cterminus of the HC of a full-length IgG molecule of different specificity (37) . A drawback of these formats is their low expression levels in mammalian cells, probably due to its both large size (~ 200kDa) and structural complexity. Recently, by fusing a bispecific diabody to the Fc domain of an IgG, we constructed a tetravalent BsAb, the "Di-diabody", that could be efficiently expressed in mammalian cells (13) . The Didiabody demonstrated potent dual-targeting activity both in vitro and in vivo, but showed significant instability in mice due to the lack of covalent linkage between the two polypeptide chains constituting the bispecific molecule -the antibody lost greater than 50% of binding activity at 72 h post administration (our unpublished observation). The approach we described here, by directly fusing a sVD antibody to the N-terminus of a full length IgG antibody of a different specificity, resulted in the production of a tetravalent (ie., two binding sites to each target), Fc domain-containing BsAb that could be efficiently expressed in mammalian cells and be purified to homogeneity with a single-step affinity chromatography. The binding affinities of the BsAb to both mPDGFRα and mVEGFR2 were significantly (2 to 4-fold) higher than those of its monospecific, monovalent Fab counterparts (Table  2) , demonstrating the benefit of bivalency antibody/antigen interaction within one BsAb molecule. In addition, although the BsAb showed lower binding activity (and affinity) to immobilized receptors (in both ELISA and BIAcore analysis, Fig. 5C and D, and Table 2 ) compared to its monospecific bivalent parent antibodies, the molecule was more efficient in interacting with cells that express both mPDGFRα and mVEGFR2 (Fig. 5E ) -clearly a result of dual receptor-targeting. Since the sVD antibody was genetically linked to the IgG, the BsAb should possess a good stability for in vivo indications. Finally, like in the Di-diabody format (13) , the intact natural Fc domain is expected to retain full capability in mediating immune effector functions including both antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity.
The prototype sVD antibody we utilized in this study, clone 1F2, was derived from a large Fab phage display library via immunopanning on immobilized mPDGFRα. Identification of sVD (VL or VH only) antibodies from both Fab and scFv phage display libraries has been, although infrequent, previously reported (38; our unpublished data). Recent progress in antibody scaffold engineering has led to the production of a number of sVD antibody libraries, including those from the scaffolds of camelid VhH (39-41), human VH or VL (42, 43) , lipocalins (44), shark V-NAR (45, 46), Protein A IgG-binding Z domain (47), and fibronectin type III domain (48) (for reviews, see 49-51). With the availability of these libraries, sVD antibodies to various antigens can be readily identified. These sVD represent excellent building blocks for the construction of bi-or multispecific antibody molecules in both fragment and, especially, the IgG-like formats (for review, see 49-51). For example, in addition to the sVD-IgG fusion BsAb described in this report, it is also possible to construct a BsAb that is theoretically identical to a normal IgG molecule, by linking a VL sVD and a VH sVD to the N-terminal of the CL and the CH1, respectively. In theory, the sVD can be paired in various combinations including VH/VL, VL/VL and VH/VH, for the construction both fragment and IgG-like BsAb molecules. It is plausible that, however, the non-cognate VL and VH pair may interact with each other in an "unwanted" or "undesirable" fashion, leading to not only a disruption of molecular folding but also an interference (thus loss) of antigen-binding activity of individual sVD in the final product (our unpublished observation). In order to assure the production of an active BsAb molecule, it is, therefore, imperative to identify the appropriate sVD pair by testing carefully the effect of interaction between the selected sVD antibodies.
An apparent concern associated with the sVD-IgG fusion BsAb format described here is that the direct fusion of a polypeptide (such as a sVD) to the N-terminus of an IgG may affect the overall folding as well as the antigen binding efficiency of the latter molecule. The observation that the antigen-binding affinity of 1F2-2B4IgG to mVEGFR2 is ~ 4-fold lower than that of the monospecific 2B4 IgG appears in support of this notion. An obvious alternative to address this issue is to link the sVD to the C-terminus of the HC of the IgG to form an IgG-sVD fusion. In fact, in a separate study, we linked the 1F2 VH onto the C-terminus of the HC of an IgG antibody directed against mPDGFRβ antibody, 1B3. The resultant BsAb, 1B3IgG-1F2 fusion, retained full antigen binding efficiency to both mPDGFRβ and mPDGFRα (our unpublished observations). Taken together, our sVD/IgG fusion format, either as sVD-IgG (N-terminus fusion) or IgG-sVD (Cterminus fusion), provides a novel and simple recombinant approach to the production of Fc domain-containing, IgG-like BsAb. 
FOOTNOTES
Abbreviations used in this paper: BsAb, Bispecific antibody; CDR, complementarity determining regions; Ig, immunoglobulin; LC, light chain; HC, heavy chain; V, variable; VL, variable light chain; VH, variable heavy light; sVD, single variable domain; PDGF, platelet derived growth factor; mPDGFRα, mouse PDGF receptor α; VEGF, vascular endothelial growth factor; mVEGFR2, mouse VEGF receptor 2; RT, room temperature; PBS, phosphate buffered saline; HRP, horse radish peroxidase.
FIGURE LEGENDS Fig 1
Deduced amino acid sequences of the VH and the VL domains of the anti-mPDGFRα antibodies and the anti-mVEGFR2 antibody, 2B4. All the complementarity determining regions (CDRs) are defined according to Kabat's definition (27) . After wash, the plates were incubated with an anti-human-Fc antibody-HRP conjugate, followed by development of the plates as described above. Data shown represent the mean ± SD of duplicate samples. (A and B) , the BsAb or the monospecific antibodies were first incubated with mPDGFR-α or mVEGFR2 in solution and then transferred to a microtiter plate coated with the second receptor, mVEGFR2 (A) mPDGFR-α (B), followed by incubation with a biotin-labeled polyclonal antibody to the first receptor (the receptor in solution), mPDGFR-α or mVEGFR2. The plate was developed after further incubation with a streptoavidin-HRP conjugate. 1C11, a control antibody to human VEGFR2. In the direct binding assay (C and D), various amounts of antibodies were first incubated in a 96-well plate precoated with mPDGFRα-Fc (C) or VEGFR2-Fc (D) fusion protein, followed by incubation with an anti-human-κ antibody HRP conjugate. Data shown represent the mean ±SD of duplicate samples. (E) FACS analysis of the bispecific 1F2-2B4IgG for binding to eEnd.1 cells. The cells were incubated with 2B4 IgG, 1F2-CH/CL or 1F2-2B4IgG at 4ºC for 1 h, followed by incubation with a PE-labeled goat anti-human Fc antibody for an additional hour, and analysis on a Guava Easycyte System. 
Fig. 7
Inhibition of PDGF and VEGF-stimulated receptor phosphorylation by the bispecific 1F2-2B4IgG. eEnd.1 cells were first incubated with various antibodies at 37°C for 30 min, followed by stimulation with VEGF or PDGF at 37°C for 15 min. After cell lysis, the receptors were immunoprecipitated from the cell lysate supernatant by incubation with an anti-mPDGFRα or an anti-mVEGFR2 antibody, followed by ProA/G-sepharose beads. The precipitated receptor proteins were resolved on a 4-12% Nupage Bis-Tris gel and transferred to a polyvinylidene difluoride membrane. Phospho-mVEGFR2 and phospho-mPDGFRα were detected on the blot using an anti-phospho-tyrosine antibody-HRP conjugate. Total receptor proteins loaded on the gel were assayed with antibodies to mPDGFRα or mVEGFR2. b CL domain deletion due to a stop codon in the N-terminus of CL resulted from a frame-shift mutation within the CDR3. c Entire VL-CL domain deletion due to a stop codon in the N-terminus of VL resulted from a frame-shift mutation. d Binding to immobilized mPDGFRα receptor protein as determined by a semi-quantitative phage-based ELISA. +, OD450nm < 0.5; ++, OD450nm between 0.5 to 2.0; and +++, OD450nm >2.0. e Blockade of mPDGFRα/PDGF-AA interaction as determined by a semi-quantitative phage-based ELISA assay.
-, no blocking; +, ++ and +++ indicate a blocking potency of 35-50%, 51-75%, and > 75%, respectively. 
Shen et al., 13
Shen et al., 14
Figure 1 1E10  ETTLTQSPGTLSLSPGERGTLSCRSSQSV····TRNYLAWYQQKAGQAPRLLIYGASSRATGIPLRFSGSGSGTDFTLTISGLEPEDFAVYFCQQYEISPPTFGGGTKVEIKR  1A11  DVVMTQSPLSLPVTPGEPASISCRSSRSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALRTPLTFGPGTKVDIKR  3B2  ETTLTQSPGTLSLSPGERATLSCRASQSV····SSSNLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLWTFGQGTKVEIKR  1C10 DIVMTHTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQPPQLLIYEVSNRFSGVPERFSGSGSGTAFTLKISRVEAEDVGVYYCMQRIEFPP^PHFRRRDQGGDQTNCGCTICLHLPAI* 3G7 AW* 1F9 QVQLQE@····································································································@LEIKR 1F2 QVQLQE@····································································································@LEIKR
2B4 QLQLQESGGGLVQPGGSLKLSCAASGFTFSS··YGMHWVRQAPGKGLEWVAVIWYDGSN·KYYADSVKGRFTISRDNSRNTLYLQMNSLRAEDTAVYYCATYPFGVVHN···WGQGTLVTVSS
VL
|----------FR1--------|------CDR1-----|-----FR2------|-CDR2--|------------FR3---------------|--CDR3---|----FR4----|
2B4 EIVLTQSPLSLPVTPGEPASISCRSSQSLLHSNGFNYLDWYLQKPGQSPHLLIYFGSYRASGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQNLQTPWTFGQGTKVDIKR
Note: ^: frame-shift mutation due to a single nucleotide insertion in the CDR3 region, leading to a shift in reading frame. *: stop-codon due to frame-shift mutations. @...@: almost the entire VL was deleted due to an in-frame deletion. Shen et al., 23
Shen et al., 15
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